Your browser doesn't support javascript.
loading
The Natural History After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Population-Based Cohort Study From the United States.
Barnes, Edward L; Desai, Aakash; Hashash, Jana G; Farraye, Francis A; Kochhar, Gursimran S.
Afiliación
  • Barnes EL; Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Desai A; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Hashash JG; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Farraye FA; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Kochhar GS; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Am J Gastroenterol ; 2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38888231
ABSTRACT

INTRODUCTION:

There are limited data regarding the natural history after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The principal objectives of this study were to identify 4 key outcomes in the natural history after IPAA within 1, 3, 5, and 10 years the incidence of pouchitis, Crohn's-like disease of the pouch, use of advanced therapies after IPAA, and pouch failure requiring excision in a network of electronic health records.

METHODS:

We performed a retrospective cohort study in TriNetX, a research network of electronic health records. In addition to evaluating incidence rates, we also sought to identify factors associated with pouchitis and advanced therapy use within 5 years of IPAA after 11 propensity score matching, expressed as adjusted hazard ratios (aHRs).

RESULTS:

Among 1,331 patients who underwent colectomy with IPAA for UC, the incidence of pouchitis increased from 58% in the first year after IPAA to 72% at 10 years after IPAA. After propensity score matching, nicotine dependence (aHR 1.61, 95% confidence interval [CI] 1.19-2.18), antitumor necrosis factor therapy (aHR 1.33, 95% CI 1.13-1.56), and vedolizumab prior to colectomy (aHR 1.44, 95% CI 1.06-1.96) were associated with an increased risk of pouchitis in the first 5 years after IPAA. The incidence of Crohn's-like disease of the pouch increased to 10.3% within 10 years of IPAA while pouch failure increased to 4.1%. The incidence of advanced therapy use peaked at 14.4% at 10 years after IPAA.

DISCUSSION:

The incidence of inflammatory conditions of the pouch remains high in the current era, with 14% of patients requiring advanced therapies after IPAA.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Am J Gastroenterol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Am J Gastroenterol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos